We use cookies to enhance your browsing experience, analyze website traffic, and maintain essential site functionality. By clicking "Accept All", you consent to our use of cookies. For more details, please review our Privacy Policy.

Cullinan Oncology Stock (NASDAQ:CGEM)



Previous Close

$9.53

52W Range

$9.06 - $30.19

50D Avg

$11.22

200D Avg

$16.68

Market Cap

$539.19M

Avg Vol (3M)

$523.96K

Beta

-0.16

Div Yield

-

CGEM Company Profile


Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

85

IPO Date

Jan 08, 2021

Website

CGEM Performance


Total Return %
1D
5D
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
CGEM
S&P 500
-2.83%
-7.03%
-9.75%
-31.15%
-44.58%
-25.26%
-46.78%
-35.11%
-69.04%
-69.04%
0.29%
1.16%
2.33%
3.97%
10.32%
4.59%
23.10%
40.82%
81.60%
191.01%

CGEM Financial Summary


Dec 23Dec 22Dec 21
Revenue--$18.94M
Operating Income$-190.65M$144.65M$-67.95M
Net Income$-153.16M$111.21M$-65.04M
EBITDA$-190.34M$-408.92M$-67.95M
Basic EPS$-3.69$2.38$-1.51
Diluted EPS$-3.69$2.38$-1.51

Fiscal year ends in Dec 23 | Currency in USD

Latest News


Latest Sec Filing


8-KJan 29, 25 | 7:00 AM
4Jan 07, 25 | 5:00 PM
4Dec 27, 24 | 6:00 PM
4Dec 20, 24 | 5:00 PM
4Dec 20, 24 | 5:00 PM
4Dec 20, 24 | 5:00 PM
4Dec 16, 24 | 5:00 PM
SC 13G/ANov 14, 24 | 5:05 PM
SC 13G/ANov 14, 24 | 4:24 PM
SC 13G/ANov 12, 24 | 2:23 PM
SC 13GNov 08, 24 | 2:17 PM
4Nov 07, 24 | 5:30 PM
10-QNov 07, 24 | 7:18 AM
8-KNov 07, 24 | 7:06 AM
SC 13G/ANov 04, 24 | 11:18 AM
SCHEDULE 13G/AOct 31, 24 | 12:48 PM
SC 13GOct 22, 24 | 3:24 PM
8-KOct 16, 24 | 7:17 AM
8-KSep 17, 24 | 7:13 AM
4Sep 09, 24 | 5:30 PM
3Aug 09, 24 | 6:00 PM
4Aug 09, 24 | 5:00 PM
10-QAug 08, 24 | 7:20 AM
8-KAug 08, 24 | 7:15 AM
4Jul 09, 24 | 5:30 PM

Peer Comparison


TickerCompany
MLYSMineralys Therapeutics, Inc.
RVMDRevolution Medicines, Inc.
CCCCC4 Therapeutics, Inc.
IPSCCentury Therapeutics, Inc.
ZNTLZentalis Pharmaceuticals, Inc.
AUTLAutolus Therapeutics plc
BOLTBolt Biotherapeutics, Inc.
DAWNDay One Biopharmaceuticals, Inc.
LYRALyra Therapeutics, Inc.
SANASana Biotechnology, Inc.
LYELLyell Immunopharma, Inc.
GLUEMonte Rosa Therapeutics, Inc.
OLMAOlema Pharmaceuticals, Inc.
EWTXEdgewise Therapeutics, Inc.
VORVor Biopharma Inc.
ACETAdicet Bio, Inc.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools